Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study
By J. Lechien, C. Chiesa-Estomba, Daniele R. De Siati, M. Horoi, S. L. Le Bon, Alexandra Rodríguez, D. Dequanter, S. Blecic, Fahd El Afia, L. Distinguin and 23 more. European Archives of Oto-Rhino-Laryngology, 2020
2,456 citations recorded by the source corpus.
Objective To investigate the occurrence of olfactory and gustatory dysfunctions in patients with laboratory-confirmed COVID-19 infection. Methods Patients with laboratory-confirmed COVID-19 infection were recruited from 12 European hospitals. The following epidemiological and clinical outcomes have been studied: age, sex, ethnicity, comorbidities, and general and otolaryngological symptoms. Patients completed olfactory and gustatory questionnaires based on the smell and taste component of the National Health and Nutrition Examination Survey, and the short version of the Questionnaire of Olfactory Disorders-Negative Statements (sQOD-NS). Results A total of 417 mild-to-moderate COVID-19 patients completed the study (263 females). The most prevalent general symptoms consisted of cough, myalgia, and loss of appetite. Face pain and nasal obstruction were the most disease-related otolaryngological symptoms. 85.6% and 88.0% of patients reported olfactory and gustatory dysfunctions, respectively. There was a significant association between both disorders ( p < 0.001). Olfactory dysfunction (OD) appeared before the other symptoms in 11.8% of cases. The sQO-NS scores were significantly lower in patients with anosmia compared with normosmic or hyposmic individuals ( p = 0.001). Among the 18.2% of patients without nasal obstruction or rhinorrhea, 79.7% were hyposmic or anosmic. The early olfactory recovery rate was 44.0%. Females were significantly more affected by olfactory and gustatory dysfunctions than males ( p = 0.001). Conclusion Olfactory and gustatory disorders are prevalent symptoms in European COVID-19 patients, who may not have nasal symptoms. The sudden anosmia or ageusia need to be recognized by the international scientific community as important symptoms of the COVID-19 infection.
Subfields: Biomedical Engineering, Neurology, Sensory Systems
View Paper: https://www.semanticscholar.org/paper/1307bd5d4d04d0f8ffca133390cc120ee764804a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Biomedical Engineering
In Neurology
Citations in the corpus
- Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19 (2020, background): “Olfactory and gustatory dysfunctions have been reported in many patients with COVID-19, suggesting the involvement of the olfactory bulb in SARS-CoV-2 infection [93, 94].”
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues (2020, positive): “We collected fromboth tissue sites because of early reports of anosmia in COVID-19 (Lechien et al., 2020).”
- COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection (2021, background): “This finding is consistent with data that points out the SARS-CoV-2 effects on gustatory and olfactory dysfunctions in COVID-19 patients [43, 44].”